JaiVenky
2021-12-29
Great
Novavax shares dropped another 4% in premarket trading<blockquote>Novavax股价在盘前交易中又下跌4%</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696588038,"tweetId":"696588038","gmtCreate":1640735494922,"gmtModify":1640735495226,"author":{"id":3585210617348402,"idStr":"3585210617348402","authorId":3585210617348402,"authorIdStr":"3585210617348402","name":"JaiVenky","avatar":"https://static.tigerbbs.com/097793f3135b5fb8cb3f03847d72bf1a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":25,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great</p></body></html>","htmlText":"<html><head></head><body><p>Great</p></body></html>","text":"Great","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696588038","repostId":1138246031,"repostType":4,"repost":{"id":"1138246031","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640683578,"share":"https://www.laohu8.com/m/news/1138246031?lang=zh_CN&edition=full","pubTime":"2021-12-28 17:26","market":"us","language":"en","title":"Novavax shares dropped another 4% in premarket trading<blockquote>Novavax股价在盘前交易中又下跌4%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138246031","media":"Tiger Newspress","summary":"Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.\n\nWhy ","content":"<p>Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.</p><p><blockquote>Novavax股价在盘前交易中又下跌4%。该股昨日暴跌近11%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/04a11fff9a31214bbcf7595183a5d305\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Why Novavax Stock Is Sinking</b></p><p><blockquote><b>为什么Novavax股价下跌</b></blockquote></p><p> The company didn't announce any new developments. So what's behind the big decline?</p><p><blockquote>该公司没有宣布任何新的进展。那么大跌的背后是什么呢？</blockquote></p><p> Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p><p><blockquote>其他疫苗股的跌幅也没有那么大。有些甚至涨了一点。这排除了对奥密克戎变种的担忧下降是Novavax股价下跌的主要因素的可能性。</blockquote></p><p> Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p><p><blockquote>相反，投资者可能对Novavax计划向美国申请其COVID-19疫苗NVX-CoV2373紧急使用授权(EUA)越来越焦虑。一些投资者还可能担心Novavax向美国食品和药物管理局(FDA)提交的文件的质量，即使它的提交没有再次出现延迟。</blockquote></p><p> CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p><p><blockquote>首席执行官斯坦利·埃尔克接受雅虎采访！上周四的财经直播可能无助于安抚投资者。当被问及何时完成FDA备案时，Erck回答说：“可能是下周，但我坚持认为我们将在今年年底前完成这项工作。”</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p><p><blockquote>只要Novavax在新年尽快完成提交，NVX-CoV2373在美国的申请再次延迟对该公司来说不会是灾难性的。然而，管理层的信誉肯定会再次受到重大打击。</blockquote></p><p> But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p><p><blockquote>但目前推测Novavax本周不会完成美国EUA备案还为时过早。担心该公司FDA包装的质量也是没有用的。Novavax最近获得了NVX-CoV2373的欧盟授权。这表明疫苗制造商能够成功满足监管机构的生产质量障碍。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p><p><blockquote>投资者不喜欢等待，但这正是他们目前对Novavax必须做的事情。该公司现在可以随时完成EUA备案。它还可能在等待监管决定的其他国家获得新的授权。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax shares dropped another 4% in premarket trading<blockquote>Novavax股价在盘前交易中又下跌4%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax shares dropped another 4% in premarket trading<blockquote>Novavax股价在盘前交易中又下跌4%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-28 17:26</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.</p><p><blockquote>Novavax股价在盘前交易中又下跌4%。该股昨日暴跌近11%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/04a11fff9a31214bbcf7595183a5d305\" tg-width=\"843\" tg-height=\"618\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> <b>Why Novavax Stock Is Sinking</b></p><p><blockquote><b>为什么Novavax股价下跌</b></blockquote></p><p> The company didn't announce any new developments. So what's behind the big decline?</p><p><blockquote>该公司没有宣布任何新的进展。那么大跌的背后是什么呢？</blockquote></p><p> Other vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p><p><blockquote>其他疫苗股的跌幅也没有那么大。有些甚至涨了一点。这排除了对奥密克戎变种的担忧下降是Novavax股价下跌的主要因素的可能性。</blockquote></p><p> Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p><p><blockquote>相反，投资者可能对Novavax计划向美国申请其COVID-19疫苗NVX-CoV2373紧急使用授权(EUA)越来越焦虑。一些投资者还可能担心Novavax向美国食品和药物管理局(FDA)提交的文件的质量，即使它的提交没有再次出现延迟。</blockquote></p><p> CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p><p><blockquote>首席执行官斯坦利·埃尔克接受雅虎采访！上周四的财经直播可能无助于安抚投资者。当被问及何时完成FDA备案时，Erck回答说：“可能是下周，但我坚持认为我们将在今年年底前完成这项工作。”</blockquote></p><p> <b>So what</b></p><p><blockquote><b>那又怎样</b></blockquote></p><p> Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p><p><blockquote>只要Novavax在新年尽快完成提交，NVX-CoV2373在美国的申请再次延迟对该公司来说不会是灾难性的。然而，管理层的信誉肯定会再次受到重大打击。</blockquote></p><p> But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p><p><blockquote>但目前推测Novavax本周不会完成美国EUA备案还为时过早。担心该公司FDA包装的质量也是没有用的。Novavax最近获得了NVX-CoV2373的欧盟授权。这表明疫苗制造商能够成功满足监管机构的生产质量障碍。</blockquote></p><p> <b>Now what</b></p><p><blockquote><b>现在怎么办</b></blockquote></p><p> Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p><p><blockquote>投资者不喜欢等待，但这正是他们目前对Novavax必须做的事情。该公司现在可以随时完成EUA备案。它还可能在等待监管决定的其他国家获得新的授权。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138246031","content_text":"Novavax shares dropped another 4% in premarket trading.The stock plunged nearly 11% yesterday.\n\nWhy Novavax Stock Is Sinking\nThe company didn't announce any new developments. So what's behind the big decline?\nOther vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.\nInstead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.\nCEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"\nSo what\nYet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.\nBut it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.\nNow what\nInvestors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1996,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696588038"}
精彩评论